VTRO

Vitro Biopharma, Inc. is a biotechnology company targeting autoimmune diseases and inflammatory disorders, with an ancillary focus in the research services and cosmeceutical fields. The Company is focused on developing therapeutic products, its stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. The Company is engaged in the development of cellular therapeutic candidates intended to address significant unmet medical needs. In the United States, the Company is authorized to conduct two clinical trials under two Food and Drug Administration (FDA) Investigational New Drug applications to assess the safety and efficacy of AlloRx Stem Cell therapy in PTHS and Long COVID. It is also engaged in various other activities, including providing research services and stem cell products, as well as cosmeceuticals, through its wholly owned subsidiary, namely InfiniVive MD.